medigraphic.com

2010, Number 4

<< Back Next >>

Enf Infec Microbiol 2010; 30 (4)

Macrolide antibiotics for pediatric infections

Ortega GAE

Language: Spanish
References: 17
Page: 134-138
PDF size: 71.12 Kb.


ABSTRACT

The macrolide activity against Chlamydia pneumoniae, Mycoplasma pneumoniae and Bordetella pertussis has been considered as being first choice. For patients with penicillin hypersensitivity macrolides are an alternative. Their anti-inflammatory and immunomodulatory effects in lung diseases (asthma, cystic fibrosis, bronchiestasis) not associated with antibacterial activity has been described. Some side effects are recognized, however, but are mild or minimum.


REFERENCES

  1. Klein JO. “History of macrolide use in pediatrics”. Ped Infect Dis J 1997; 16(4): 427-431.

  2. Neal HS. “Macrolides”, in: Mandell L. Gerald. Infections Diseases. 2002. 5ta ed., tomo I: 370-377.

  3. MacCkacken GH. “Microbiology activities of the Newer macrolide antibiotics”. Ped Infect Dis J 1997; 16(4): 432-437.

  4. Lonk JR, Garau J, Medeiras A. “Implications of an-timicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: The case of macrolides”. J Antimicrob Chemother 2002; 50(S3): 87-94.

  5. Arrieta A, Singh J. “Management of recurrent and per-sistent acute otitis media: New options with familiar antibiotics”. Ped Infect Dis J 2004; 23(S2): 115-124.

  6. Low DE, Pichichero ME, Schaad UB. “Optimizing an-tibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resis-tance”. Clin Ped 2004; 43(2): 135-151.

  7. Jacobs M, Jonson C. “Macrolide resistance: an increas-ing concern for treatment failure in children”. Ped Infect Dis J 2003: 22(s8) 131-138.

  8. Lino Y, Sasaki Y, Miyasawa T, et al. “Nasopharyngeal flora and drug susceptibility in children with macrolide therapy”. Laryngoscope 2003; 113(10): 1780-1785.

  9. Hyde TB, Gay KU, et al. Macrolide resistance among invasive streptococcus pneumoniae isolates”. JAMA 2001; 286(15): 1857-1862.

  10. Mason EO, Wald ER, Bradley J, et al. “Macrolide resistance among middle ear isolates of Streptococcus pneu-moniae observed at eight United States pediatric centers: Prevalence of M and MLSB phenotypes”. Ped Infect Dis J 2003; 22(7): 623-628.

  11. Jaffe A, Bush A. “Anti-inflammatory effects of mac-rolides in Lung diseases. Ped Pneumonol 2001; 31(3): 137-148.

  12. Rubin BK, Henke MO.”Inmunomodulatory activity and effectiveness of macrolides in chronic airway disease”. Chest 2004; 1 25(2): 70-78.

  13. Wallwork B, Camon W, Mackay SA, et al. “A double- blind, randomized, placebo controlled trial of macrolide in the treatment of chronic rhinosinusitis”. Larynco-scope 2006; 116(2): 189-193.

  14. Garey KW, Alvani A, Danziger LH, et al. “Tissue repara-tive effects of macrolide antibiotics in chronic inflam-matory sinopulmonary diseases”. Chest 2003; 123(1): 261-265.

  15. Casey JP, Michael E. “Metaanalysis of short course antibiotic treatment for group A streptococcal tonsil-lopharyngitis”. Ped Infect Dis J 2005; 24(10): 909-917.

  16. Gonzalez, B E., Martinez AG., Mason EO. “Azithromy-cin compared with [beta]-Lactam antibiotic treatment failures in pneumococcal infections of children”. Ped Infect Dis J 2004; 23(5): 399-405.

  17. Field SK, Cowie RL. “Treatment of Mycobacterium aviu-mintracellulare complex lung disease with a macrolide, Etambutol, and Clofazimine”. Chest 2003; 124(4): 1482-186.




2020     |     www.medigraphic.com